Yahoo Finance

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

SEATTLE, September 02, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival ...
Yahoo Finance

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Stockhouse

2024-12-19 | Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint - Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA | NDAQ ...

Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ ...
Investing

Narsoplimab shows promise in TA-TMA survival rates

SEATTLE - Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company with a market capitalization of $534 million and notably volatile stock movements (Beta 1.98), has revealed results from ...
Investing

Omeros reports survival benefit with narsoplimab in TA-TMA

Omeros (NASDAQ:OMER) Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various diseases. The company is ...
Morningstar

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult ...
Finanznachrichten

Omeros Corporation: Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with ...
Yahoo Finance

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an ...